Axel Grothey, MD

 

The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey.

 

Click the link below to read the full editorial:

Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer – A New Standard of Care

X